Back to Search
Start Over
Risk of Breakthrough SARS-CoV-2 Infections in Adult Transplant Recipients.
- Source :
-
Transplantation [Transplantation] 2021 Nov 01; Vol. 105 (11), pp. e265-e266. - Publication Year :
- 2021
-
Abstract
- Competing Interests: D.L.S. received honoraria for consulting and speaking from Sanofi, Novartis, CSL Behring, Jazz Pharmaceuticals, Veloxis, Mallinckrodt, and Thermo Fisher Scientific. R.K.A has received study/grant support from Aicuris, Astellas, Chimerix, Merck, Oxford Immunotec, Qiagen, and Takeda/Shire. S.A. received grant support from the Cystic Fibrosis Foundation, received consulting honoraria from Merck and Gilead, and was an unpaid consultant for BioMX. The other authors declare no conflicts of interest.
- Subjects :
- Adult
COVID-19 immunology
COVID-19 virology
COVID-19 Vaccines immunology
Centers for Disease Control and Prevention, U.S. statistics & numerical data
Graft Rejection immunology
Graft Rejection prevention & control
Humans
Immunosuppressive Agents administration & dosage
Immunosuppressive Agents adverse effects
Mass Vaccination statistics & numerical data
Risk Assessment statistics & numerical data
SARS-CoV-2 immunology
United States epidemiology
COVID-19 epidemiology
Organ Transplantation adverse effects
Transplant Recipients statistics & numerical data
Subjects
Details
- Language :
- English
- ISSN :
- 1534-6080
- Volume :
- 105
- Issue :
- 11
- Database :
- MEDLINE
- Journal :
- Transplantation
- Publication Type :
- Report
- Accession number :
- 34310531
- Full Text :
- https://doi.org/10.1097/TP.0000000000003907